Virmedex
Virmedex is a Barcelona-based deep tech company specializing in immersive healthcare professional training through gamified virtual simulators, video games, VR, and AI. Their key products include virCPB, a cardiopulmonary bypass training platform; virECMO, an ECMO training video game; and Dex, an AI-powered chatbot for ECMO and perfusion training. The company combines scientifically validated models with engaging game mechanics to enhance motivation and learning effectiveness. Originating from the Technical University of Catalonia, Virmedex collaborates with hospitals, research centers, and companies to deliver tailored medical device training solutions. Their business model is primarily SaaS and subscription-based, targeting healthcare professionals and institutions worldwide.
Virmedex
Virmedex is a Barcelona-based deep tech company specializing in immersive healthcare professional training through gamified virtual simulators, video games, VR, and AI. Their key products include virCPB, a cardiopulmonary bypass training platform; virECMO, an ECMO training video game; and Dex, an AI-powered chatbot for ECMO and perfusion training. The company combines scientifically validated models with engaging game mechanics to enhance motivation and learning effectiveness. Originating from the Technical University of Catalonia, Virmedex collaborates with hospitals, research centers, and companies to deliver tailored medical device training solutions. Their business model is primarily SaaS and subscription-based, targeting healthcare professionals and institutions worldwide.
TL;DR
Location: Barcelona, Spain
Founded: 2022
Core products: virCPB, virECMO, Dex (AI assistant)
Team size: 7 employees
Business model: SaaS / subscription
Recent funding: €150,000 pre-seed/seed (Feb 2024, lead: Grow Venture Partners)
Company Overview
Problem Domain
Healthcare professional training and simulation for complex procedures (perfusion, ECMO, cardiopulmonary bypass).
Founded
2022
Industry
Healthtech / Medical training
Tech Stack
Funding Track Record
€150,000
Reported closed round in Feb 2024; company communications and third‑party databases list €150k led by Grow Venture Partners.
Investor Signal
“Lead investor: Grow Venture Partners”